查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1840688

心血管设备市场按设备类型、操作类型、存取类型、应用程式和最终用户划分－2025-2032 年全球预测

Cardiovascular Devices Market by Device Type, Operation Type, Access Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年心血管设备市场将成长至 1,097.9 亿美元，复合年增长率为 8.02%。

主要市场统计数据
基准年2024年 592.1亿美元
预计2025年 637.7亿美元
预测年份：2032年 1097.9亿美元
复合年增长率（%） 8.02%

一份简明而权威的心血管设备说明，涵盖临床需求、技术曲折点、监管环境以及医院、门诊和家庭医疗保健相关人员的策略重点。

循环系统器械生态系统正经历一段转折期，其驱动力来自临床需求、技术进步以及不断变化的监管预期。临床医生日益要求能够提高诊断准确性、减少手术创伤并实现长期远端监控的解决方案，而支付方则要求产品在疗效和成本效益方面具有可证明的价值。在此背景下，製造商必须在更短的产品开发週期与更高的可证明需求之间取得平衡，而医疗保健系统则必须在技术创新的采用与有限的资本和劳动力资源之间取得平衡。

科技融合正在再形成医疗设备的设计、检验和整合到护理路径的方式。嵌入式感测器、互联互通平台和人工智慧主导的分析等数位健康赋能技术增强了传统设备的功能，使更主动的疾病管理和真实世界的效能评估成为可能。同时，材料科学和微创技术的进步正在提高安全性，并扩大介入治疗的覆盖范围。这些转变正在推动商业策略、临床试验设计和上市后监测的重新定位，以了解长期疗效并支持报销方案。

从以产品为中心转向以生态系统为中心，对于持续成功至关重要。那些将研发投资与明确的临床终点相结合、及早建立付款人关係并展现出应对全球监管和供应链复杂性准备的公司，将更有能力将技术前景转化为对患者和系统层面的有意义的影响。本报告首先说明了这些驱动因素，并为领导者提供了对未来情况和随之而来的策略选择的系统性理解。

深入检验心血管设备开发和交付的变革性转变，包括数位化、微创应用、不断变化的法规和供应链弹性

多项变革性变革正在重新定义心血管器材的开发、应用和报销方式。首先，临床医生偏好缩短住院时间和加快康復速度，加上器械输送系统和影像引导技术的不断改进，这些因素正在加速微创和经皮治疗的发展。这一趋势正在波及整个临床路径，扩大了对相容诊断工具和围手术期管理设备的需求，同时也重塑了介入团队的培训要求。

其次，数位化和互联互通已超越附加功能，成为核心产品差异化优势。具备安全遥测功能、可与电子健康记录整合并支援预测分析的设备，透过支援远端监控、依从性追踪以及设备相关併发症的早期检测，正在增加切实的价值。然而，这些功能也带来了网路安全、资料管治和互通性标准的新挑战，製造商和医疗系统必须携手应对。

第三，监管生态系统正在不断发展，以适应新的设备范式和软体主导的功能。监管机构越来越重视真实世界证据和上市后资料收集，以补充上市前评估。这种转变激励设备开发人员将强大的上市后监测和数据收集机制纳入其产品生命週期，并透过早期科学建议和灵活的证据产生策略与奖励互动。

第四，供应链弹性和筹资策略正变得日益重要。零件供应商的全球分布、关键材料的集中风险以及地缘政治动态，迫使企业进行采购多元化，在可行的情况下进行近岸外包，并采用能够降低关税风险和产能中断影响的合约结构。此类营运转型通常需要在供应商合格、库存管理和情境规划方面进行投资。

最后，相关人员对基于价值的成果和成本透明度的期望正在影响采购和合约模式。付款人和提供者都要求提供证据，证明医疗设备有助于降低医疗总成本、改善功能结果并减少再入院率。因此，商业团队必须将临床证据与经济模型和实际结果数据结合，以支持差异化的定价和合约方法。这种转变需要研发、监管、商业和营运职能部门制定整合策略，这既带来了机会，也带来了复杂性。

重点分析2025年即将实施的美国关税对医疗设备采购、定价策略、供应商合约、临床采购和跨国投资决策的累积影响。

2025年美国关税的实施，为整个心血管设备生态系统的采购、製造和定价策略增添了新的复杂性。关税导致零件和组件的投入成本上升，这可能会挤压製造商的利润，促使其重新评估采购布局和合约条款。在许多情况下，采购团队正在考虑多方采购、双重采购和策略性库存缓衝，以确保生产的连续性并履行对客户的承诺。

虽然拥有垂直整合能力或本地製造地的製造商可能更有能力吸收和减轻关税的影响，但依赖专业海外供应商的公司面临更严峻的调整。这些发展加速了关键零件回流或近岸外包的讨论，但资本支出和资质认证时间仍然是重新配置的关键限制因素。因此，采购和营运领导者正在权衡短期成本吸收、将成本转嫁给客户以及对供应链敏捷性的长期投资之间的利弊。

随着采购週期和竞标评估适应新的成本标准，临床医生和医疗系统也将感受到间接影响。医院和门诊中心必须协调预算压力与临床需求，以部署能够改善疗效的先进医疗设备。这种矛盾促使人们更加重视可证明的价值和合约创新，包括基于疗效的合约以及协调製造商、供应商和付款人之间奖励机制的风险分担安排。

最后，关税将影响策略伙伴关係和资本配置。投资者和企业发展团队正在重新调整跨境交易、许可安排和製造投资，以应对政策驱动的成本波动。在这种环境下，透明的供应商关係规划、情境规划以及与付款方和采购相关人员的积极互动，对于保持市场进入和竞争差异化至关重要。

深入的細項分析揭示了设备类别、操作和存取方式、临床应用以及推动临床采用模式和采购优先顺序的最终用户动态

细緻的细分视角阐明了不同设备类别、操作模式、存取技术、临床应用和最终用户偏好如何相互作用，从而影响采用动态和采购优先顺序。就设备类型而言，诊断和监测设备（涵盖心电图系统、电极导线和配件、心臟事件记录器、心电图监测和植入式动态心电图监测仪）越来越多地在连接性、数据品质和与护理路径的整合方面进行评估。在迭代成像和治疗流程中，对心臟支架、导管、心臟瓣膜和血管移植物等外科手术设备的输送特性、生物相容性材料和寿命进行评估。血压计、去心房颤动和起搏器等治疗设备需要专注于长期可靠性、电池寿命创新以及与远端追踪平台相容性的证据。

侵入式和非侵入式器械在操作类型的划分上，凸显了其在开发和应用上的差异。侵入式治疗方法通常需要复杂的临床培训、冗长的监管流程以及大量的术前和术后支持，而非侵入式治疗方法则更注重易用性、患者依从性和门诊病人整合。经皮和静脉产品类型之间的差异会影响感染风险、操作流程和患者选择标准，从而影响产品设计和临床讯息。

按应用细分，包括心律管理、冠状动脉疾病、週边血管疾病和中风管理，说明了治疗重点如何影响证据要求和护理路径整合。用于心律管理的设备必须提供清晰的感知和治疗阈值演算法，而冠状动脉介入治疗则越来越强调针对病变的传递能力和抗血管再阻塞性能。週边和神经血管应用具有独特的解剖学和动态复杂性，推动了设备客製化和程序支援系统的发展。

门诊手术中心、居家医疗和医院/诊所的最终用户细分清楚地表明了购买行为、资金限制和临床工作流程的差异。门诊手术中心优先考虑能够实现高效週转和可预测围手术全期过程的设备。居家照护解决方案需要以患者为中心的设计、远端监控功能以及对非临床看护者的明确指导。医院和诊所根据企业范围的通讯协定、报销模式和跨专业互通性来评估设备。这种细分有助于定义与每个相关利益者的营运现实一致的临床证据策略、定价模型和商业化路径。

区域策略视角探索美洲、欧洲、中东和非洲以及亚太地区将如何影响创新管道、监管途径、报销模式和商业化路线

区域动态对监管路径、报销框架和商业化策略有着重大影响，因此需要采取量身定制的方法。在美洲，监管机构和大型综合医疗系统正在推动具有明显临床和经济效益的解决方案的快速采用。采购环境通常涉及特定医疗系统内的集中竞标，也涉及私人医院和门诊中心之间的分散采购，因此需要差异化的销售和证据策略。

欧洲、中东和非洲的监管协调努力和多样化的支付模式，导致市场进入途径差异很大。采用集中式医疗技术评估 (HTA) 流程的国家强调比较有效性和成本效益分析，而其他国家则依赖价格谈判和区域采购协议。在某些司法管辖区，报销决策越来越依赖真实世界临床试验和註册，这鼓励器材製造商在进行早期临床试验的同时，规划长期证据的产生。

亚太地区拥有快速应用的潜力，但受监管成熟度和定价压力的限制。该地区的市场格局各异，既有高度成熟的监管体系，青睐主导创新解决方案；也有价格敏感型市场，注重成本效益和本地製造合作。临床资料在地化、监管参与度和分销管道策略往往是商业性成功的关键。

在全部区域，策略考量集中在监管协调、本地证据产生和通路伙伴关係。开发商必须平衡全球产品蓝图与当地监管和报销现实，投资于能够反映当地决策驱动因素的针对性临床试验和付款人参与计划。这种区域观点体现在上市顺序策略、证据产生计划和伙伴关係模式中，以优化可近性并管理商业性风险。

对企业策略的实际评估，展示研发重点、垂直整合、伙伴关係、监管参与和以结果为导向的商业模式如何塑造竞争定位

主要企业正在展现深度临床关注与生态系统导向策略的融合。投资重点倾向于将核心设备功能与数位化能力结合，并与软体和分析公司合作，从设备产生的数据中获取临床洞察。研发组合日益体现出迭代产品改进与平台计画之间的平衡，以实现模组化升级和扩展服务产品。

企业发展活动有两个关键主题：垂直整合关键製造能力以提高韧性；并建立策略联盟以加速获取互补技术和分销网络。併购和授权交易正在积极开展，以填补能力缺口，尤其是在先进材料、设备内建感测器和云端基础分析等领域。那些致力于与监管机构进行早期和持续对话，并将上市后资料收集功能融入其产品的公司，正在确保更顺畅的路径过渡，并为付款人提供更具吸引力的价值提案。

商业模式正朝着以结果为导向，与医疗服务提供者网路和付款人建立关係的方向发展。早期采用者正在试行风险分担安排和捆绑支付方式，将报酬与病患结果和资源利用率挂钩。此外，那些精简服务和耗材物流、提供完善的临床教育并支持医院工作流程整合的公司往往能获得更高的采用率。总体而言，公司的成功越来越依赖将产品开发与扩充性的服务、证据生成以及能够满足付款人和提供者优先事项的自适应商业模式相结合。

为行业领导者提供可行的策略建议，以使研发设计、监管策略、商业化和供应链弹性与临床要求和付款人的期望保持一致。

产业领导者应优先考虑一系列将策略意图与营运成果连结的综合行动。首先，透过设计既能捕捉临床终点又能反映真实世界绩效指标的临床试验，将证据生成从一开始就融入产品开发中。这种双重证据流程不仅支持监管申报，还能透过展示以病人为中心的成果和潜在的系统级成本节约，加强与付款人的谈判。

其次，透过制定清晰的设备连接、数据互通性和分析主导服务的蓝图，加速数位整合。儘早优先考虑网路安全和资料管治，以减少与机构客户和监管机构之间的下游摩擦。将设备性能与可操作的分析相结合，以提高临床效用，并创造新的基于价值的服务提案。

第三，从弹性和成本可预测性的角度重新评估您的供应链策略。实现关键零件供应商多元化，尽可能考虑近岸外包策略性零件，并实施合约保障措施以因应政策波动。制定基于情境的紧急时应对计画，将使您能够快速应对关税和中断，同时又不牺牲品质或合规性。

第四，根据区域和最终用户的细微差别客製化您的商业化策略：将定价和存取模式与当地报销实际情况相结合，在需要的地方投资当地证据，并部署结合临床教育、现场支援和数位参与的混合销售模式，以优化医院、门诊中心和居家医疗环境中的采用。

最后，寻求选择性的伙伴关係和有针对性的併购，以填补材料、软体和製造​​方面的能力差距。利用联盟加快上市时间并扩展临床应用，同时确保您的整合计画保持临床品质和法规合规性。总而言之，这些建议提供了一条切实可行的途径，在管理商业性和营运风险的同时保持创新。

调查方法的透明度，详细说明主要和次要研究方法、专家检验、数据三角测量和品管，以确保分析的严谨性和可重复性

调查方法将结构化的专家级一手资料研究与严谨的二手证据整合相结合，以确保分析的稳健性。主要资讯包括与介入性心臟病专家、电生理学家、采购负责人、付款方以及前监管审查人员的访谈，以发现实际限制因素、未满足的临床需求以及采购决策驱动因素。此外，我们还与临床负责人和卫生经济学家进行了咨询会议，以补充这些定性见解，从而检验证据优先顺序和终点选择。

二次研究涵盖同行评审文献、监管指南文件、临床註册分析以及公开的製造商技术文献，旨在建立全面的依证。我们运用数据三角测量技术，协调不同资讯来源，并检验关于装置功能、临床应用模式和操作要求的关键主张。在适用的情况下，我们将程序趋势和器械使用案例整合起来，并与临床实践指南和共识声明进行交叉引用。

品管包括将访谈结果与已记录的临床结果和设备性能报告进行交叉检验，由匿名专家进行额外检验，以及根据咨询委员会的回馈对假设进行迭代改进。调查方法和资料来源透明，报告附录详细说明了访谈类别、文献筛选标准和检验程序，以支持研究结果的可重复性和客户可信度。

对研究结果的简要总结，强调了相关人员应优先考虑的策略要务、营运风险和近期行动，以保持临床影响和商业性可行性

总而言之，心血管设备领域正在经历一场结构性转变，转向整合、实证主导和数位化的解决方案。临床对微创、可靠和连网型设备的需求与付款方对可证明价值的期望正趋于一致，这为市场准入和持续应用设定了高门槛。关税相关的压力和供应链的复杂性加剧了营运的紧迫性，凸显了製定弹性筹资策略和动态定价模型的必要性。

积极整合纵向证据、实施有针对性的区域策略并将商业模式与临床工作流程相结合的利益相关人员，将能够更好地获益于创新，同时降低下行风险。製造商、医疗保健提供者和付款人之间以透明数据共用和基于结果的协议为中心的协作方式，为扩展新技术并带来可衡量的患者效益提供了切实可行的途径。本文提出的综合分析旨在为在不同的医疗保健环境中平衡临床影响、监管确定性和商业性可行性的策略选择提供参考。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 微创心血管设备的进步改善了患者的治疗效果
  • 越来越多人采用穿戴式心血管监测仪进行即时健康追踪
  • 将人工智慧和机器学习融入心血管设备诊断和治疗
  • 可生物降解支架的发展提高了安全性并减少了併发症
  • 药物释放型支架的创新提高了患者的康復率
  • 扩展心血管疾病管理的远端监控系统
  • 3D列印技术在客製化心血管植入製造的应用
  • 机器人辅助心血管手术需求的增加导致手术精确度的提高
  • 开发具有增强功能的下一代植入式心臟整流去颤器
  • 专注于透过基因和生物标记分析进行个人化心血管治疗

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 心血管设备市场（依设备类型）

  • 诊断和监测设备
    • 心电图系统
    • 电极导线及配件
    • 心臟事件记录器
    • 心电图监测
    • 嵌入式循环录音机
  • 手术设备
    • 心臟支架
    • 导管
    • 心臟瓣膜
    • 血管移植
  • 治疗设备
    • 血压计
    • 去心房颤动
    • 起搏器

第九章心血管设备市场运作类型）

  • 侵入性设备
  • 非侵入式设备

第 10 章：心血管设备市场进入类型）

  • 经皮
  • 静脉

第 11 章：心血管设备市场（按应用）

  • 心律管理
  • 冠状动脉疾病
  • 週边血管疾病
  • 中风管理

第 12 章：心血管设备市场（依最终用户）

  • 门诊手术中心
  • 居家护理
  • 医院和诊所

13. 心血管设备市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 14 章：心血管设备市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章心血管设备市场（按国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Abbott Laboratories
    • ACS Diagnostics
    • Alivecor, Inc.
    • Asahi Kasei Corporation
    • B. Braun SE
    • Baxter International Inc.
    • Bexen Medical
    • Biotronik SE & Co KG
    • Boston Scientific Corporation
    • BPL Medical Technologies Private Limited
    • Edwards Lifesciences Corporation
    • GE Healthcare
    • HeartFlow Holding, Inc.
    • Johnson & Johnson Services, Inc.
    • Koninklijke Philips NV,
    • Lepu Medical Technology（Beijing）Co.,Ltd.
    • LivaNova PLC
    • Medtronic PLC
    • Microport Scientific Corporation
    • Nihon Kohden Corporation
    • Schiller AG
    • Siemens Healthineers
    • Terumo Cardiovascular Systems Corporation
    • Tricog Health
    • Vesalius Cardiovascular Inc.
    • Zoll Medical Corporation
Product Code: MRR-D2073C5D8E6E

The Cardiovascular Devices Market is projected to grow by USD 109.79 billion at a CAGR of 8.02% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 59.21 billion
Estimated Year [2025] USD 63.77 billion
Forecast Year [2032] USD 109.79 billion
CAGR (%) 8.02%

A concise and authoritative orientation to the cardiovascular devices landscape framing clinical needs, technology inflection points, regulatory dynamics, and strategic priorities for stakeholders across hospitals, ambulatory care, and home settings

The cardiovascular devices ecosystem stands at an inflection point driven by converging clinical imperatives, technology advances, and evolving regulatory expectations. Clinicians increasingly demand solutions that deliver diagnostic precision, reduce procedural trauma, and enable longitudinal remote monitoring, while payers push for demonstrable value in outcomes and cost effectiveness. Against this backdrop, manufacturers must reconcile shorter product development cycles with higher evidentiary demands, and health systems must balance adoption of innovation against constrained capital and workforce capacity.

Technological convergence is reshaping how devices are designed, validated, and integrated into care pathways. Digital health enablers such as embedded sensors, connectivity platforms, and AI-driven analytics are augmenting traditional device functionality, enabling more proactive disease management and real-world performance assessment. Simultaneously, advances in materials science and minimally invasive techniques are improving safety profiles and expanding eligibility for interventional therapies. These shifts prompt a reorientation of commercial strategies, clinical trial design, and post-market surveillance to capture longitudinal outcomes and support reimbursement narratives.

Transitioning from product-centric to ecosystem-centric approaches will be critical for sustained success. Companies that align their R&D investments with clear clinical endpoints, cultivate payer engagement early, and demonstrate operational readiness for global regulatory and supply chain complexities will be better positioned to translate technological promise into meaningful patient and system-level impact. This report opens with an orientation to these forces to equip leaders with a structured view of the landscape and the strategic choices that follow.

An in-depth examination of transformative shifts altering cardiovascular device development and delivery including digitization, minimally invasive adoption, regulatory evolution, and supply chain resilience

Several transformative shifts are redefining how cardiovascular devices are developed, adopted, and reimbursed. First, the trajectory toward minimally invasive and percutaneous interventions has accelerated, driven by clinician preference for reduced hospital stays and faster recovery, and by iterative improvements in device delivery systems and imaging guidance. This trend has ripple effects across clinical pathways, amplifying demand for compatible diagnostic tools and peri-procedural management devices, while reshaping training requirements for interventional teams.

Second, digitization and connectivity have moved beyond incremental features to become core product differentiators. Devices that provide secure telemetry, integrate with electronic health records, and enable predictive analytics add tangible value by supporting remote monitoring, adherence tracking, and early detection of device-related complications. These capabilities, however, introduce new challenges in cybersecurity, data governance, and interoperability standards that manufacturers and health systems must address collaboratively.

Third, regulatory ecosystems are evolving to accommodate novel device paradigms and software-driven functionality. Regulators are increasingly emphasizing real-world evidence and post-market data collection to complement pre-market evaluations. This shift incentivizes device developers to build robust post-market surveillance and data capture mechanisms into product lifecycles, and to engage with regulatory authorities through early scientific advice and flexible evidence generation strategies.

Fourth, supply chain resilience and sourcing strategies have gained strategic importance. The global distribution of component suppliers, concentration risks for critical materials, and geopolitical dynamics are prompting companies to adopt diversified sourcing, nearshoring where feasible, and contractual structures that mitigate tariff exposure and capacity disruptions. These operational shifts often require investment in supplier qualification, inventory management, and scenario planning.

Lastly, stakeholder expectations around value-based outcomes and cost transparency are influencing procurement and contracting models. Payers and providers are seeking evidence that devices contribute to reduced total cost of care, improved functional outcomes, and fewer readmissions. As a result, commercial teams must couple clinical evidence with economic modeling and real-world outcome data to support differentiated pricing and contracting approaches. Together, these shifts create both opportunity and complexity, requiring integrated strategies across R&D, regulatory, commercial, and operations functions.

A focused analysis of the cumulative impact of United States tariffs introduced in 2025 on device sourcing, pricing strategies, supplier contracts, clinical procurement, and cross-border investment decisions

The introduction of United States tariffs in 2025 has added a distinct layer of complexity to procurement, manufacturing, and pricing strategies across the cardiovascular device ecosystem. Tariff-induced input cost increases for components and subassemblies can compress manufacturer margins, prompting reassessment of sourcing footprints and contract terms. In many cases, procurement teams are exploring multi-sourcing, dual-sourcing, and strategic inventory buffers to insulate production continuity and protect customer commitments.

Manufacturers with vertically integrated capabilities or localized manufacturing nodes may be better positioned to absorb or mitigate tariff impacts, whereas firms reliant on specialized offshore suppliers face steeper adjustments. This dynamic is accelerating conversations about reshoring or nearshoring for critical components, though capital expenditures and qualification timelines remain material constraints for reconfiguration. Consequently, procurement and operations leaders are weighing the trade-offs between short-term cost absorption, price pass-through to customers, and longer-term investments in supply chain agility.

Clinicians and health systems also feel secondary effects as purchasing cycles and tender evaluations adjust to new cost baselines. Hospitals and ambulatory centers must reconcile budgetary pressures with the clinical imperative to adopt advanced devices that improve outcomes. This tension is encouraging greater emphasis on demonstrable value and contractual innovation, including outcome-based agreements and risk-sharing arrangements that align incentives among manufacturers, providers, and payers.

Finally, tariffs have implications for strategic partnerships and capital allocation. Investors and corporate development teams are recalibrating cross-border deals, licensing arrangements, and manufacturing investments to account for policy-driven cost variability. In this environment, transparent supplier mapping, scenario planning, and proactive engagement with payers and procurement stakeholders are essential to preserve market access and maintain competitive differentiation.

Insight-driven segmentation analysis revealing device categories, operation and access modalities, clinical applications, and end-user dynamics that determine clinical adoption patterns and procurement priorities

A nuanced segmentation lens clarifies how different device classes, operational modalities, access techniques, clinical applications, and end-user settings interact to shape adoption dynamics and procurement priorities. When considering device type, diagnostic and monitoring instruments-spanning ECG systems, electrode leads and accessories, event monitors, Holter monitors, and implantable loop recorders-are increasingly evaluated for their connectivity, data quality, and integration with care pathways. Surgical devices such as cardiac stents, catheters, heart valves, and vascular grafts are being assessed for delivery profile, biocompatible materials, and longevity under repeat imaging and therapeutic algorithms. Therapeutic devices that include blood pressure monitors, defibrillators, and pacemakers require focused evidence on long-term reliability, battery life innovations, and compatibility with remote follow-up platforms.

Operation type delineation between invasive devices and non-invasive devices highlights divergent development and adoption considerations. Invasive therapies often necessitate complex clinical training, lengthy regulatory pathways, and substantive peri-procedural support, while non-invasive devices prioritize ease of use, patient adherence, and outpatient integration. Access type distinctions between transcutaneous and transvenous modalities carry implications for infection risk, procedural logistics, and patient selection criteria, which in turn inform both product design and clinical messaging.

Application-specific segmentation-cardiac rhythm management, coronary artery disease, peripheral vascular disease, and stroke management-demonstrates how therapeutic focus affects evidence requirements and care pathway integration. Devices intended for rhythm management must present clear algorithms for sensing and therapeutic thresholds, while coronary interventions increasingly emphasize lesion-specific deliverability and anti-restenotic performance. Peripheral vascular and neurovascular applications bring their own anatomical and hemodynamic complexities that drive device customization and procedural support systems.

End-user segmentation across ambulatory surgical centers, home care, and hospitals and clinics underlines differing purchasing behaviors, capital constraints, and clinical workflows. Ambulatory surgical centers prioritize devices that enable efficient turnover and predictable perioperative courses. Home care solutions demand patient-centric design, remote monitoring capabilities, and clear instructions for non-clinical caregivers. Hospitals and clinics evaluate devices in the context of enterprise-wide protocols, reimbursement models, and cross-specialty interoperability. Taken together, this layered segmentation approach informs targeted clinical evidence strategies, pricing models, and commercialization pathways that better align with the operational realities of each stakeholder group.

A regional strategic lens exploring how Americas, Europe Middle East & Africa, and Asia-Pacific influence innovation pipelines, regulatory pathways, reimbursement models, and commercialization routes

Regional dynamics materially influence regulatory pathways, reimbursement frameworks, and commercialization strategies, requiring geographically tailored approaches. In the Americas, regulatory agencies and large integrated health systems shape rapid uptake for solutions that demonstrate clear clinical and economic benefits. The procurement environment often involves centralized tendering in certain health systems, but also fragmented purchasing across private hospitals and ambulatory centers, which necessitates differentiated sales and evidence strategies.

In Europe, Middle East & Africa, regulatory harmonization efforts and the diversity of payer models create a mosaic of market access pathways. Countries with centralized HTA processes emphasize comparative effectiveness and cost-consequence analyses, while others rely on negotiated pricing and regional procurement agreements. In several jurisdictions, reimbursement decisions increasingly hinge on real-world performance evidence and registries, encouraging device makers to plan longitudinal evidence generation alongside initial clinical studies.

The Asia-Pacific region presents rapid uptake potential tempered by diverse regulatory maturity and pricing pressures. Markets in this region range from highly sophisticated systems that favor premium, innovation-led solutions to price-sensitive environments where cost-efficiency and local manufacturing partnerships are critical. Localization of clinical data, regulatory engagement, and distribution channel strategies are often decisive factors for commercial success.

Across these geographies, strategic considerations converge around regulatory alignment, local evidence generation, and channel partnerships. Developers must balance global product roadmaps with local regulatory and reimbursement realities, investing in targeted clinical studies and payer engagement plans that reflect regional decision drivers. This regional lens informs sequencing strategies for launches, evidence accumulation plans, and partnership models that optimize access while managing commercial risk.

A pragmatic assessment of corporate strategies showing how R&D focus, vertical integration, partnerships, regulatory engagement, and outcome-oriented commercial models shape competitive positioning

Leading companies in the cardiovascular devices arena are demonstrating a blend of deep clinical focus and ecosystem-oriented strategies. Investment priorities skew toward integrating digital capabilities with core device functionality, partnering with software and analytics firms to extract clinical insights from device-generated data. R&D portfolios increasingly reflect a balance between iterative product improvements and platform initiatives that enable modular upgrades and extended service offerings.

Corporate development activity has two dominant themes: vertical integration of critical manufacturing capabilities to improve resilience and strategic partnerships that accelerate access to complementary technologies or distribution networks. Mergers and acquisitions, as well as licensing deals, are being executed to fill capability gaps-particularly in areas such as advanced materials, device-embedded sensors, and cloud-based analytics. Regulatory savvy is a differentiator; organizations that invest in early and ongoing dialogue with authorities, and that build post-market data capture into their offerings, secure smoother pathway transitions and more persuasive value propositions for payers.

Commercial models are evolving toward outcome-oriented relationships with provider networks and payers. Early adopters are piloting risk-sharing agreements and bundled payment approaches that tie reimbursement to patient outcomes and resource utilization. Additionally, companies that streamline service and consumables logistics, provide robust clinical education, and support hospital workflow integration tend to achieve stronger adoption curves. Overall, company success increasingly depends on aligning product development with scalable services, evidence generation, and adaptive commercial models that respond to payer and provider priorities.

Actionable strategic recommendations for industry leaders to align R&D design, regulatory strategy, commercialization, and supply chain resilience with clinical imperatives and payer expectations

Industry leaders should prioritize a set of integrated actions that translate strategic intent into operational outcomes. First, embed evidence generation into product development from the outset by designing clinical studies that capture both clinical endpoints and real-world performance metrics. This dual evidence stream supports regulatory submissions and strengthens payer negotiations by demonstrating patient-centered outcomes and potential system-level savings.

Second, accelerate digital integration by developing clear roadmaps for device connectivity, data interoperability, and analytics-driven services. Prioritize cybersecurity and data governance early to reduce downstream friction with institutional customers and regulators. Coupling device performance with actionable analytics will enhance clinical utility and create new value-based service propositions.

Third, reassess supply chain strategies through the lens of resilience and cost predictability. Diversify supplier bases for critical components, consider nearshoring for strategic parts when feasible, and implement contractual safeguards that address policy volatility. Scenario-based contingency planning will enable faster responses to tariff or disruption events without sacrificing quality or compliance.

Fourth, tailor commercialization strategies to regional and end-user nuances. Align pricing and access models with local reimbursement realities, invest in targeted local evidence generation where required, and deploy hybrid sales models that blend clinical education, field support, and digital engagement to optimize adoption across hospitals, ambulatory centers, and home care settings.

Finally, pursue selective partnerships and targeted M&A to close capability gaps in materials, software, and manufacturing. Use alliances to accelerate time to market and expand clinical applications, while ensuring that integration plans preserve clinical quality and regulatory compliance. Collectively, these recommendations provide a pragmatic pathway to sustain innovation while managing commercial and operational risks.

Methodological transparency detailing primary and secondary research approaches, expert validation, data triangulation, and quality controls used to ensure analytical rigor and reproducibility

The research approach combined structured primary engagement with subject matter experts and a rigorous secondary evidence synthesis to ensure analytic robustness. Primary inputs included interviews with interventional cardiologists, electrophysiologists, procurement leaders, payers, and former regulatory reviewers to surface practical constraints, unmet clinical needs, and procurement decision drivers. These qualitative insights were complemented by advisory sessions with clinical trialists and health economists to validate evidence priorities and endpoint selection.

Secondary research encompassed peer-reviewed literature, regulatory guidance documents, clinical registry analyses, and publicly available manufacturers' technical literature to construct a comprehensive evidence base. Data triangulation techniques were applied to reconcile divergent sources and to validate key assertions about device functionality, clinical adoption patterns, and operational requirements. Where applicable, synthesis of procedural trends and device use-cases was corroborated with clinical practice guidelines and consensus statements.

Quality controls included cross-validation of interview findings against documented clinical outcomes and device performance reports, anonymized verification with additional experts, and iterative refinement of assumptions with advisory panel feedback. The methodology emphasized transparency in data sources and analytical assumptions, and the report includes appendices that document interview categories, literature selection criteria, and validation steps to support reproducibility and client confidence in the findings.

A concise concluding synthesis reinforcing strategic imperatives, operational risks, and near-term actions stakeholders should prioritize to sustain clinical impact and commercial viability

In conclusion, the cardiovascular devices landscape is undergoing structural shifts that favor integrated, evidence-driven, and digitally enabled solutions. Clinical demand for minimally invasive, reliable, and connected devices converges with payer expectations for demonstrable value, creating a high bar for market entry and sustained adoption. Tariff-related pressures and supply chain complexities add operational urgency, underscoring the need for resilient sourcing strategies and dynamic pricing models.

Stakeholders that proactively embed longitudinal evidence capture, pursue targeted regional strategies, and align commercial models with clinical workflows will be better positioned to capture the benefits of innovation while mitigating downside risks. Collaborative approaches among manufacturers, providers, and payers-anchored by transparent data sharing and outcome-based agreements-offer a pragmatic route to scale new technologies and deliver measurable patient benefit. The synthesis presented here is intended to inform strategic choices that balance clinical impact, regulatory certainty, and commercial viability across diverse care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in minimally invasive cardiovascular devices improving patient outcomes
  • 5.2. Rising adoption of wearable cardiovascular monitors for real-time health tracking
  • 5.3. Integration of AI and machine learning in cardiovascular device diagnostics and treatments
  • 5.4. Growth of biodegradable stents enhancing safety and reducing complications
  • 5.5. Innovations in drug-eluting stents driving better recovery rates in patients
  • 5.6. Expansion of remote monitoring systems for cardiovascular disease management
  • 5.7. Emergence of 3D printing technology in custom cardiovascular implant fabrication
  • 5.8. Increasing demand for robotic-assisted cardiovascular surgeries boosting precision
  • 5.9. Development of next-generation implantable cardioverter-defibrillators with enhanced features
  • 5.10. Focus on personalized cardiovascular therapies through genetic and biomarker analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiovascular Devices Market, by Device Type

  • 8.1. Diagnostic & Monitoring Devices
    • 8.1.1. ECG Systems
    • 8.1.2. Electrode Leads & Accessories
    • 8.1.3. Event Monitors
    • 8.1.4. Holter Monitors
    • 8.1.5. Implantable Loop Recorders
  • 8.2. Surgical Devices
    • 8.2.1. Cardiac Stents
    • 8.2.2. Catheters
    • 8.2.3. Heart Valves
    • 8.2.4. Vascular Grafts
  • 8.3. Therapeutic Devices
    • 8.3.1. Blood Pressure Monitors
    • 8.3.2. Defibrillators
    • 8.3.3. Pacemakers

9. Cardiovascular Devices Market, by Operation Type

  • 9.1. Invasive Devices
  • 9.2. Non-Invasive Devices

10. Cardiovascular Devices Market, by Access Type

  • 10.1. Transcutaneous
  • 10.2. Transvenous

11. Cardiovascular Devices Market, by Application

  • 11.1. Cardiac Rhythm Management
  • 11.2. Coronary Artery Disease
  • 11.3. Peripheral Vascular Disease
  • 11.4. Stroke Management

12. Cardiovascular Devices Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Home Care
  • 12.3. Hospitals & Clinics

13. Cardiovascular Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cardiovascular Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cardiovascular Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. ACS Diagnostics
    • 16.3.3. Alivecor, Inc.
    • 16.3.4. Asahi Kasei Corporation
    • 16.3.5. B. Braun SE
    • 16.3.6. Baxter International Inc.
    • 16.3.7. Bexen Medical
    • 16.3.8. Biotronik SE & Co KG
    • 16.3.9. Boston Scientific Corporation
    • 16.3.10. BPL Medical Technologies Private Limited
    • 16.3.11. Edwards Lifesciences Corporation
    • 16.3.12. GE Healthcare
    • 16.3.13. HeartFlow Holding, Inc.
    • 16.3.14. Johnson & Johnson Services, Inc.
    • 16.3.15. Koninklijke Philips N.V.,
    • 16.3.16. Lepu Medical Technology(Beijing)Co.,Ltd.
    • 16.3.17. LivaNova PLC
    • 16.3.18. Medtronic PLC
    • 16.3.19. Microport Scientific Corporation
    • 16.3.20. Nihon Kohden Corporation
    • 16.3.21. Schiller AG
    • 16.3.22. Siemens Healthineers
    • 16.3.23. Terumo Cardiovascular Systems Corporation
    • 16.3.24. Tricog Health
    • 16.3.25. Vesalius Cardiovascular Inc.
    • 16.3.26. Zoll Medical Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CARDIOVASCULAR DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CARDIOVASCULAR DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CARDIOVASCULAR DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY ECG SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY ECG SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY ECG SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY ECG SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY ECG SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY ECG SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY ELECTRODE LEADS & ACCESSORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY ELECTRODE LEADS & ACCESSORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY ELECTRODE LEADS & ACCESSORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY ELECTRODE LEADS & ACCESSORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY ELECTRODE LEADS & ACCESSORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY ELECTRODE LEADS & ACCESSORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY EVENT MONITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY EVENT MONITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY EVENT MONITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY EVENT MONITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY EVENT MONITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY EVENT MONITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOLTER MONITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOLTER MONITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOLTER MONITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOLTER MONITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOLTER MONITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOLTER MONITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY IMPLANTABLE LOOP RECORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY IMPLANTABLE LOOP RECORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY IMPLANTABLE LOOP RECORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY IMPLANTABLE LOOP RECORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY IMPLANTABLE LOOP RECORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY IMPLANTABLE LOOP RECORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CARDIAC STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CARDIAC STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CARDIAC STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CARDIAC STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CARDIAC STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CARDIAC STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HEART VALVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HEART VALVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HEART VALVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HEART VALVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HEART VALVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HEART VALVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY VASCULAR GRAFTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY VASCULAR GRAFTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY VASCULAR GRAFTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY VASCULAR GRAFTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY VASCULAR GRAFTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY VASCULAR GRAFTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY BLOOD PRESSURE MONITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY BLOOD PRESSURE MONITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY BLOOD PRESSURE MONITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY BLOOD PRESSURE MONITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY BLOOD PRESSURE MONITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY BLOOD PRESSURE MONITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DEFIBRILLATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DEFIBRILLATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DEFIBRILLATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DEFIBRILLATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DEFIBRILLATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DEFIBRILLATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY PACEMAKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY PACEMAKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY PACEMAKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY PACEMAKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY PACEMAKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY PACEMAKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY INVASIVE DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY INVASIVE DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY INVASIVE DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY INVASIVE DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY INVASIVE DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY INVASIVE DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY NON-INVASIVE DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY NON-INVASIVE DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY NON-INVASIVE DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY NON-INVASIVE DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY NON-INVASIVE DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY NON-INVASIVE DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY TRANSCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY TRANSCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY TRANSCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY TRANSCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY TRANSCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY TRANSCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY TRANSVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY TRANSVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY TRANSVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY TRANSVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY TRANSVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY TRANSVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CARDIAC RHYTHM MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CARDIAC RHYTHM MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CARDIAC RHYTHM MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CARDIAC RHYTHM MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CARDIAC RHYTHM MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CARDIAC RHYTHM MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY STROKE MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY STROKE MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY STROKE MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY STROKE MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY STROKE MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY STROKE MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC CARDIOVASCULAR DEVICES MARKET SIZE, BY